Long Non-Coding RNA and Chemoresistance in Bladder Cancer – A Mini Review-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long Non-Coding RNA and Chemoresistance in Bladder Cancer – A Mini Review

Published:2022-11-14 Issue:2 Volume:41 Page:164-172
ISSN:0735-7907
Container-title:Cancer Investigation
language:en
Short-container-title:Cancer Investigation

Author:

Lima Ana Paula Braga¹^ORCID,da Silva Glenda Nicioli¹²³

Affiliation:

1. Programa de Pós-graduação em Ciências Farmacêuticas (CIPHARMA), Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil

2. Programa de Pós-graduação em Ciência Biológicas (CBIOL), Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil

3. Departamento de Análises Clínicas (DEACL), Escola de Farmácia, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil

Funder

Universidade Federal de Ouro Preto

CNPq

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/07357907.2022.2146703

Reference83 articles.

1. Epidemiology of Bladder Cancer

2. Tumor vesical: presente y futuro

3. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer

4. Downstaging of Muscle-Invasive Bladder Cancer Using Neoadjuvant Gemcitabine and Cisplatin or Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as Single Regimens or as Switch Therapy Modalities

5. Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent progress and the emerging role of lncRNAs in cancer drug resistance; focusing on signaling pathways;Pathology - Research and Practice;2024-01

2. The role of E3 ubiquitin ligases and deubiquitinases in bladder cancer development and immunotherapy;Frontiers in Immunology;2023-05-05

3. LncRNA JHDM1D-AS1 Is a Key Biomarker for Progression and Modulation of Gemcitabine Sensitivity in Bladder Cancer Cells;Molecules;2023-03-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3